Navigation Links
Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
Date:5/31/2013

IRVING, Texas, May 31, 2013 /PRNewswire/ -- Caris Life Sciences™, a leading biosciences company focused on fulfilling the promise of personalized medicine, today announced it intends to expand its Next-Generation Sequencing (NGS) capabilities to include whole exome and transcriptome sequencing.  The offering will provide physicians with an in-depth report focusing on the 452 well-documented somatic alterations present across all cancer types.

Once launched, this expanded mutational analysis will be available for order as a standalone panel or in combination with other molecular tests. This 450-plus gene profile will include all relevant genomic alterations, including translocations, rearrangements, copy number alterations, base substitutions, insertions and deletions. The expanded profile utilizes the COSMIC database to identify and include every gene that has been shown to contain alterations in any type of cancer. As new genes important to the understanding of cancer are identified, they can quickly be included in the report prepared for physicians, ensuring that patients receive the most comprehensive and up-to-date information available.  Increasing the breadth of genes profiled will provide the next level of biomarker analysis, and will complement the company's flagship molecular profiling offering, which already equips oncologists with the most clinically actionable biomarker data and drug correlations available today.

"Our molecular profiling service, Caris Molecular Intelligence™, utilizes the most relevant technologies to interrogate proteins, RNA and DNA," said David D. Halbert , Chairman and Chief Executive Officer of Caris Life Sciences. "We've found that many of our customers were curious to see more genetic mutations, so as the leading service provider in the molecular profiling space, we wanted to be responsive and further develop our DNA and RNA mutational analysis capabilities."

Based on a very sophisticated bioinformatic algorithm, Caris can combine the more than 30,000 data points in its Caris Registry warehouse with the results generated from expanded DNA mutational analysis. This unique ability will enable richer, more meaningful data outputs for future research use.

About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine. This specialty oncology reference laboratory offers more than 70 clinically relevant molecular profiling tests, including its comprehensive Caris' Molecular Intelligence™ profile. Caris Molecular Intelligence correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from the world's leading clinical cancer literature. With nearly 50,000 patients profiled, this service uses the most advanced and clinically-relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company's proprietary Carisome® platform — a blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit www.carislifesciences.com.


 


'/>"/>
SOURCE Caris Life Sciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Caris Life Sciences Symposium to Explore Advances in Next Generation Sequencing for Gynecologic Cancers
2. Caris Life Sciences nimmt Next-Generation Sequencing zur Verbesserung des evidenzbasierten Tumorprofilierungsservices für Krebspatienten auf
3. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
4. Caris Sponsors CancerCare Connect Education Workshop on Molecular Profiling in the Treatment of Breast Cancer
5. Caris Life Sciences mejora la evaluación por perfil molecular con los biomarcadores ROS1 y MGMT-metilación
6. Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers
7. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
8. Data Sciences International (DSI) in Space
9. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
10. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
11. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... 2017 , ... The Catalyst Midwest premix manufacturing facility has been ... services and private label organic services. , The first organic product is Organic 18 ... officer of Dynamite Marketing, which owns the facility. , Catalyst already has received the ...
(Date:2/24/2017)... San Diego, Calif. (PRWEB) , ... February 24, 2017 , ... ... African food and wine scene. Making stops in several cities, she gained a ... Her culinary adventure began in Stellenbosch, a town in South Africa’s Western Cape province. ...
(Date:2/24/2017)... 2017 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its unaudited financial results for the third quarter and ... 31, 2016. Third Quarter of Fiscal 2017 ... of fiscal 2017 increased by 18.6% to RMB200.9 million ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... leading digital health company, and Digital Noema ... and remote patient monitoring, announce they are partnering ... DN Telehealth maximizes collaboration compatibility for ... consultations beyond a physical clinical setting to include ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/7/2017)... WARSAW, Ind. , Feb. 7, 2017 ... global leader in musculoskeletal healthcare, will present at the ... Lotte New York Palace Hotel on Wednesday, February 15, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
Breaking Biology News(10 mins):